Skip to main content
CVS
NYSE Trade & Services

Director Larry Robbins' Investment Funds Sell Over $352M in CVS Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Negative
Importance info
7
Price
$92.829
Mkt Cap
$119.07B
52W Low
$58.5
52W High
$98.43
52W Position info
59% above low
Off High info
5.7% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CVS sits 59% above its 52-week low of $58.5.

Summary

Director Larry Robbins' managed investment funds sold over $352 million worth of CVS Health common stock and cash-settled swaps, marking a significant reduction in their holdings.


Key Events · Ownership and Investor Activity · CVS

  • Significant Insider Sale

    Director Larry Robbins, through Glenview Investment Funds, sold 3,750,000 shares of common stock and 378,000 units of cash-settled swaps.

  • Total Value Exceeds $352 Million

    The combined value of these transactions was $352,742,694, executed between May 19 and May 21, 2026.

  • Indirect Ownership

    The shares and swaps were held indirectly by Glenview Investment Funds, where Mr. Robbins serves as Founder, Portfolio Manager, and CIO.

  • Post-Transaction Holdings

    After these sales, the funds hold 6,213,412 shares.


Analysis · CVS · Trade & Services

Director Larry Robbins, through investment funds he manages, executed a substantial sale of CVS Health common stock and cash-settled swaps totaling over $352 million. This significant disposition by a director, even if through managed funds, represents a notable reduction in exposure and could be interpreted as a portfolio rebalancing decision or a shift in conviction.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVS was trading at $92.83 on NYSE in the Trade & Services sector, with a market capitalization of approximately $119.1B. The 52-week trading range was $58.50 to $98.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVS - Latest Insights

CVS
Nov 04, 2026, 1:48 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $80.13
Real-time Price: $83.10 info
Change: +$2.97 (+4%) info
Market Cap: $106.299B info
CVS
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $93.20
Real-time Price: $83.10 info
Change: -$10.10 (-11%) info
Market Cap: $106.299B info
CVS
Nov 04, 2026, 6:34 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $91.86
Real-time Price: $83.10 info
Change: -$8.76 (-10%) info
Market Cap: $106.299B info
CVS
Nov 04, 2026, 6:31 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.49
Real-time Price: $83.10 info
Change: -$8.39 (-9%) info
Market Cap: $106.299B info
CVS
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $91.84
Real-time Price: $83.10 info
Change: -$8.74 (-10%) info
Market Cap: $106.299B info